abstract：BACKGROUND:Acute diarrhea is the major cause of child morbidity and mortality in low-income nations. It is the second most common cause of death among children <5 years of age globally. The indispensable role of community pharmacists is clearly observed in the prevention and treatment of diarrhea. However, there is a p...

journal_title：Therapeutics and clinical risk management

authors： Abegaz TM,Belachew SA,Abebe TB,Gebresilassie BM,Teni FS,Woldie HG

更新日期：2016-04-05 00:00:00

abstract：:[This corrects the article on p. 19 in vol. 12, PMID: 26730198.]. ...

journal_title：Therapeutics and clinical risk management

authors：

更新日期：2016-03-10 00:00:00

abstract：AIM:To compare the long-term survival outcomes of radiofrequency ablation and liver resection for single very early/early stage hepatocellular carcinoma (HCC). METHODS:The Cochrane Library (Issue 3, 2015), Embase (1974 to March 15, 2015), PubMed (1950 to March 15, 2015), Web of Science (1900 to March 15, 2015), and Ch...

journal_title：Therapeutics and clinical risk management

authors： He ZX,Xiang P,Gong JP,Cheng NS,Zhang W

更新日期：2016-02-23 00:00:00

abstract：PURPOSE:To report two cases of chronic postoperative cystoid macular edema, resistant to topical therapy, treated with consecutive intravitreal injections of ketorolac tromethamine. METHODS:Four daily intravitreal injections of 500 μg/0.05 mL of ketorolac were given to each patient. Complete clinical examination and O...

journal_title：Therapeutics and clinical risk management

authors： Tsilimbaris MK,Tsika C,Kymionis GD

更新日期：2016-02-12 00:00:00

abstract：:Soft tissue sarcomas (STSs) are a group of rare tumors accounting for less than 1% of all adult malignant tumors, a heterogeneous group of more than 50 histological subtypes. Five percent to 30% of STS patients experience local recurrence and 10%-38% present with clinically detectable metastases. Doxorubicin either al...

journal_title：Therapeutics and clinical risk management

authors： Nakamura T,Matsumine A,Sudo A

更新日期：2016-01-13 00:00:00

abstract：:The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS). The objectives of this review are to summarize the most up-to-date data on long-term efficacy and safety of infliximab in AS, with special emphasis on axial and extra-articular disease, predictors of response, and radiol...

journal_title：Therapeutics and clinical risk management

authors： Elalouf O,Elkayam O

更新日期：2015-11-19 00:00:00

abstract：:Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors including lung cancer. Several angiogenesis inhibitors have been developed as potential therapies for non-small-cell lung cancer (NSCLC). Nintedanib is a small-molecule tyrosine kinase inhibitor that targets receptors f...

journal_title：Therapeutics and clinical risk management

authors： Takeda M,Okamoto I,Nakagawa K

更新日期：2015-11-16 00:00:00

abstract：:Cariprazine is a recently developed antipsychotic drug with a partial agonism for the D2 and D3 receptors. It shows a tenfold greater affinity for the D3 receptor. In clinical trials, its therapeutic effect has been tested in patients with an acute exacerbation of schizophrenia and in patients with acute mania in bipo...

journal_title：Therapeutics and clinical risk management

authors： Werner FM,Coveñas R

更新日期：2015-11-02 00:00:00

abstract：OBJECTIVE:The outcome of decompressive craniectomy (DC) for severe traumatic brain injury (sTBI) patients with fixed dilated pupils (FDPs) is not clear. The objective of this study was to validate the outcome of DC in sTBI patients with FDPs. PATIENTS:We retrospectively collected data from 207 sTBI patients with FDPs ...

journal_title：Therapeutics and clinical risk management

authors： Mao X,Miao G,Hao S,Tao X,Hou Z,Li H,Tian R,Zhang H,Lu T,Ma J,Zhang X,Cheng H,Liu B

更新日期：2015-10-22 00:00:00

abstract：BACKGROUND:Hypertension is a highly prevalent risk factor for cardiovascular disease in patients with type 1 diabetes mellitus. Elevated blood pressure (BP) promotes the development and progression of microvascular complications, eg, nephropathy and retinopathy. The purpose of this study was to identify and detect earl...

journal_title：Therapeutics and clinical risk management

authors： Shalaby NM,Shalaby NM

更新日期：2015-10-05 00:00:00

abstract：OBJECTIVE:To investigate the reactivation of the hepatitis B virus (HBV) following transarterial chemoembolization (TACE) in Chinese hepatocellular carcinoma (HCC) patients with low serum HBV DNA level, and to analyze the factors related to HBV reactivation in HCC patients with low serum HBV DNA level. METHODS:From No...

journal_title：Therapeutics and clinical risk management

authors： Shao W,Zhang F,Cong N,Li J,Song J

更新日期：2015-09-07 00:00:00

abstract：:Vorapaxar (ZONTIVITY™, formerly known as SCH 530348) is a specific, orally active antagonist of the protease-activated receptor-1 (PAR-1) on platelets. It inhibits thrombin-induced platelet activation by binding to the ectodomain of PAR-1. After animal studies and Phase II studies showed that vorapaxar sufficiently in...

journal_title：Therapeutics and clinical risk management

authors： Diehl P,Bode C,Duerschmied D

更新日期：2015-08-03 00:00:00

abstract：BACKGROUND:Internationally, there is a remarkable achievement in the areas of drug discovery, drug design, and clinical trials. New and efficient drug formulation techniques are widely available which have led to success in treatment of several diseases. Despite these achievements, large number of patients continue to ...

journal_title：Therapeutics and clinical risk management

authors： Abubakar AR,Ismail S,Rahman NI,Haque M

更新日期：2015-06-30 00:00:00

abstract：:Chordomas are rare, locally aggressive skull base neoplasms known for local recurrence and not-infrequent treatment failure. Current evidence supports the role of maximal safe surgical resection. In addition to open skull-base approaches, the endoscopic endonasal approach to clival chordomas has been reported with fav...

journal_title：Therapeutics and clinical risk management

authors： Di Maio S,Yip S,Al Zhrani GA,Alotaibi FE,Al Turki A,Kong E,Rostomily RC

更新日期：2015-05-26 00:00:00

abstract：:Experimental data indicate that several pharmacological agents that have long been used for the management of various diseases unrelated to cancer exhibit profound in vitro and in vivo anticancer activity. This is of major clinical importance, since it would possibly aid in reassessing the therapeutic use of currently...

journal_title：Therapeutics and clinical risk management

authors： Papanagnou P,Baltopoulos P,Tsironi M

更新日期：2015-05-18 00:00:00

abstract：:This study examined the associations of diabetes-related distress (DRD), depressive symptoms, health-related quality of life (HRQoL), and medication adherence with glycemia, blood pressure (BP), and lipid biomarkers in adults with type 2 diabetes mellitus (T2D). This cross-sectional study was conducted in three Malays...

journal_title：Therapeutics and clinical risk management

authors： Chew BH,Sherina MS,Hassan NH

更新日期：2015-04-29 00:00:00

abstract：INTRODUCTION:Copeptin which is the C-terminal fragment of antidiuretic hormone (ADH), is a biomarker that has been reported to be increased in various cardiovascular disorders, cerebrovascular diseases and associated with prognosis. Patients with obstructive sleep apnea syndrome (OSAS) have a tendency to develop corona...

journal_title：Therapeutics and clinical risk management

authors： Çınarka H,Kayhan S,Karataş M,Yavuz A,Gümüş A,Özyurt S,Cüre MC,Şahin Ü

更新日期：2015-04-10 00:00:00

abstract：:The Clinical Assessment Program and Teflaro(®) Utilization Registry (CAPTURE) is a multicenter study evaluating the clinical use of ceftaroline fosamil in patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infection. Data were collected between August 2011 and Februa...

journal_title：Therapeutics and clinical risk management

authors： Maggiore C,Vazquez JA,Guervil DJ,Ramani A,Jandourek A,Cole P,Friedland HD

更新日期：2015-04-02 00:00:00

abstract：:Prostacyclin is an endogenous eicosanoid produced by endothelial cells; through actions on vascular smooth-muscle cells, it promotes vasodilation. Pulmonary arterial hypertension (PAH) is characterized by elevated mean pulmonary artery pressure due to a high pulmonary vascular resistance state. A relative decrease in ...

journal_title：Therapeutics and clinical risk management

authors： LeVarge BL

更新日期：2015-03-31 00:00:00

abstract：:Japanese encephalitis (JE) is one of severe viral encephalitis that affects individuals in Asia, western Pacific countries, and northern Australia. Although 67,900 JE cases have been estimated among 24 JE epidemic countries annually, only 10,426 have been reported in 2011. With the establishment of JE surveillance and...

journal_title：Therapeutics and clinical risk management

authors： Wang H,Liang G

更新日期：2015-03-19 00:00:00

abstract：BACKGROUND AND AIMS:The aims of this study were to explore the correlation between chronic hepatitis B virus (HBV) drug-resistant mutation profiles and the efficacy of nucleoside analog rescue therapy in patients with initial antiviral treatment failure. PATIENTS AND METHODS:Patients with initial antiviral therapy fai...

journal_title：Therapeutics and clinical risk management

authors： Liang LB,Chen LL,Chen EQ,Liao J,Tang H

更新日期：2015-03-12 00:00:00

abstract：BACKGROUND:This retrospective cohort study evaluated whether manual lymphatic drainage (MLD) therapy increases the risk of recurrence of breast cancer. METHODS:We analyzed 1,106 women who were diagnosed with stage 0-3 breast cancer between 2007 and 2011 and experienced remission after surgery and adjuvant therapy. The...

journal_title：Therapeutics and clinical risk management

authors： Hsiao PC,Liu JT,Lin CL,Chou W,Lu SR

更新日期：2015-02-27 00:00:00

abstract：BACKGROUND:Traditional Chinese medicine (TCM) and Western medicine are both popular in Taiwan. Approximately 14.1% of Taiwanese residents use Western drugs and Chinese herbs concurrently; therefore, drug-herb interaction is critical to patient safety. This paper presents a new procedure for reducing the risk of drug in...

journal_title：Therapeutics and clinical risk management

authors： Lin SS,Tsai CL,Tu CY,Hsieh CL

更新日期：2015-02-16 00:00:00

abstract：BACKGROUND:The irradiation of head and neck cancer (HNC) often causes damage to the salivary glands. The resulting salivary gland hypofunction and xerostomia seriously reduce the patient's quality of life. PURPOSE:To analyze the literature of actual management strategies for radiation-induced hypofunction and xerostom...

journal_title：Therapeutics and clinical risk management

authors： Pinna R,Campus G,Cumbo E,Mura I,Milia E

更新日期：2015-02-04 00:00:00

abstract：:Lobomycosis is a subcutaneous mycosis of chronic evolution caused by the Lacazia loboi fungus. Its distribution is almost exclusive in the Americas, and it has a particularly high prevalence in the Amazon basin. Cases of lobomycosis have been reported only in dolphins and humans. Its prevalence is higher among men who...

journal_title：Therapeutics and clinical risk management

authors： Francesconi VA,Klein AP,Santos AP,Ramasawmy R,Francesconi F

更新日期：2014-10-09 00:00:00

abstract：:Trichosporon asahii is an emerging opportunistic pathogen that is life-threatening particularly for immunosuppressed patients. Only a few studies have described Trichosporon infection in kidney transplant recipients. This study reports a 67-year-old male kidney transplant recipient who developed fatal fungemia and pne...

journal_title：Therapeutics and clinical risk management

authors： Yang MF,Gao HN,Li LJ

更新日期：2014-09-30 00:00:00

abstract：:Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr virus (EBV) infection. The presence of EBV in all tumor c...

journal_title：Therapeutics and clinical risk management

authors： Hutajulu SH,Kurnianda J,Tan IB,Middeldorp JM

更新日期：2014-09-05 00:00:00

abstract：:The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. Thi...

journal_title：Therapeutics and clinical risk management

authors： Patel NK,Finianos A,Whitaker KD,Aragon-Ching JB

更新日期：2014-08-16 00:00:00

abstract：:We present two typical cases of severe complications (sepsis and hemorrhage) after negative pressure wound therapy (NPWT) in burned patients. Necrotic tissues in some deep burn wounds are difficult to judge correctly and remove thoroughly. An electrically burned blood vessel looks "intact" but can easily break. Necrot...

journal_title：Therapeutics and clinical risk management

authors： Ren H,Li Y

更新日期：2014-07-01 00:00:00

abstract：:Patients with cancer have a 6-7-fold higher risk of venous thromboembolism (VTE) as compared with non-cancer patients. Effective and safe anticoagulation for the prevention and treatment of VTE is the cornerstone of the management of patients with cancer, aiming to decrease morbidity and mortality and to improve quali...

journal_title：Therapeutics and clinical risk management

authors： Gerotziafas GT,Mahé I,Elalamy I

更新日期：2014-06-13 00:00:00

abstract：:Erectile dysfunction (ED) is often perceived by both patients and sexual partners as a serious problem that can jeopardize quality of life, psychosocial or emotional well-being, and the partnership in the long term. Since their introduction, oral phosphodiesterase type 5 inhibitors (PDE5Is) have been found to be highl...

journal_title：Therapeutics and clinical risk management

authors： Cho MC,Paick JS

更新日期：2014-05-14 00:00:00

abstract：:Coronary and cerebrovascular atherothrombosis are the leading cause of mortality and morbidity worldwide. Novel antiplatelet agents have been established for the management of patients with clinically evident coronary atherothrombosis and are increasingly used in these patients. These agents, however, have shown limit...

journal_title：Therapeutics and clinical risk management

authors： Iannopollo G,Camporotondo R,De Ferrari GM,Leonardi S

更新日期：2014-05-02 00:00:00

abstract：INTRODUCTION:Sepsis and septic shock are important causes of mortality in intensive care unit patients, hence early diagnosis and therapy are important in management of their treatment. The available information on sepsis patients is not enough to recommend or to discard the routine evaluation of triglyceride (TG) leve...

journal_title：Therapeutics and clinical risk management

authors： Cetinkaya A,Erden A,Avci D,Karagoz H,Karahan S,Basak M,Bulut K,Gencer V,Mutlu H

更新日期：2014-02-27 00:00:00

abstract：BACKGROUND:Influenza A H1N1 and H3N2 are two influenza waves that have been identified in past years. METHODS:Data from 77 inpatients from three tertiary hospitals were included and statistical analysis was performed in three different clusters. RESULTS:Thirty-four patients (44.2%) had respiratory distress upon admis...

journal_title：Therapeutics and clinical risk management

authors： Petridis D,Zarogoulidis P,Kallianos A,Kioumis I,Trakada G,Spyratos D,Papaiwannou A,Porpodis K,Huang H,Rapti A,Hohenforst-Schmidt W,Zarogoulidis K

更新日期：2014-02-07 00:00:00

abstract：BACKGROUND:The aim of this open-label, randomized, parallel-group pilot study was to evaluate the efficacy of cefditoren pivoxil and levofloxacin in terms of speed of reduction in inflammatory parameters, clinical recovery, and microbiological eradication. METHODS:Forty eligible patients with acute exacerbation of chr...

journal_title：Therapeutics and clinical risk management

authors： Blasi F,Tarsia P,Mantero M,Morlacchi LC,Piffer F

更新日期：2013-01-01 00:00:00

abstract：:There are a number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in relapsing MS patients, and is the latest disease-modif...

journal_title：Therapeutics and clinical risk management

authors： Oh J,O'Connor PW

更新日期：2013-01-01 00:00:00

abstract：INTRODUCTION:We carried out an economic analysis to assess the cost-effectiveness of highly active antiretroviral therapy (HAART) regimens in Italy for the management of human immunodeficiency virus (HIV)-infected patients according to clinical practice in the Infectious Diseases Department of "L. Sacco" Hospital, Mila...

journal_title：Therapeutics and clinical risk management

authors： Rizzardini G,Bonfanti P,Carenzi L,Coen M,Orlando G,Di Matteo S,Colombo GL

更新日期：2012-01-01 00:00:00

abstract：AIM:To evaluate the efficacy of glycopyrrolate oral solution (1 mg/5 mL) in managing problem drooling associated with cerebral palsy and other neurologic conditions. METHOD:Thirty-eight patients aged 3-23 years weighing at least 27 lb (12.2 kg) with severe drooling (clothing damp 5-7 days/week) were randomized to glyc...

journal_title：Therapeutics and clinical risk management

authors： Zeller RS,Lee HM,Cavanaugh PF,Davidson J

更新日期：2012-01-01 00:00:00

abstract：:A utilization study was performed in a 2200-bed tertiary care teaching hospital. Data mining was performed on all nasogastric medication prescriptions for patients hospitalized in 2011. Nurses were interviewed by questionnaire. A PDCA (Plan-Do-Check-Act) cycle was used for continuous quality improvement. The proportio...

journal_title：Therapeutics and clinical risk management

authors： Zhu LL,Xu LC,Wang HQ,Jin JF,Wang HF,Zhou Q

更新日期：2012-01-01 00:00:00

abstract：:Denosumab is a breakthrough biological drug approved by the Food and Drug Administration and European Medicines Agency for the treatment of osteoporosis in 2010. It is a fully human monoclonal antireceptor activator of nuclear factor kappa-B ligand antibody, which inhibits the activity of osteoclasts, resulting in an ...

journal_title：Therapeutics and clinical risk management

authors： Cavalli L,Brandi ML

更新日期：2012-01-01 00:00:00